A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient

J Oncol Pharm Pract. 2022 Jan;28(1):247-249. doi: 10.1177/10781552211027936. Epub 2021 Jul 7.

Abstract

Introduction: Capecitabine is an antimetabolite antineoplastic agent widely used in the treatment gastrointestinal cancers. The common frequently reported cutaneous adverse drug reaction associated with capecitabin are a palmar-plantar erythrodysesthesia syndrome, rash and hyperpigmentation. This case reports a capecitabine-induced palmar hypopigmentation.

Case report: We report the case of a 74-years old patient with jejunum adenocarcinoma treated by capecitabine. The patient developed a pseudo-vitiligo after 2 cycles capecitabine and without history of cutaneous disorders. The skin lesions were characterized with skin hypopigmentation on both hands.Management and outcome: The hypopigmentation slowly recovered after capecitabine discontinuation.

Conclusion: This is the first described case of pseudo-vitiligo induced by capecitabine. This impressive but non-severe adverse effect should be known by oncologists and oncology pharmacists to reassure the patients in particular about the possible recovery after discontinuation of capecitabine.

Keywords: Capecitabine/fluorouracil/adverse effects; antimetabolites; antineoplastic/pigmentation disorders/vitiligo.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma* / drug therapy
  • Aged
  • Antimetabolites, Antineoplastic / adverse effects
  • Capecitabine / adverse effects
  • Fluorouracil / adverse effects
  • Gastrointestinal Neoplasms* / drug therapy
  • Humans
  • Hypopigmentation* / chemically induced

Substances

  • Antimetabolites, Antineoplastic
  • Capecitabine
  • Fluorouracil